Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kenjiro Tsuruoka"'
Autor:
Sho Mitsuya, MD, Masahiro Arai, MD, Kiyoe Kanaoka, MD, Tomoya Funamoto, MD, Hiroyuki Tsuji, MD, Kenjiro Tsuruoka, MD, PhD, Ninso Matsunaga, MD, Takahiko Nakamura, MD, Yosuke Tamura, MD, PhD, Masafumi Imanishi, MD, PhD, Soichiro Ikeda, MD, PhD, Akihisa Imagawa, MD, PhD, Yasuhito Fujisaka, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100631- (2024)
Osimertinib administration has been approved as an adjuvant treatment after complete surgical resection in patients with EGFR-mutated NSCLC. This article presents the first report of life-threatening postoperative osimertinib-induced interstitial lun
Externí odkaz:
https://doaj.org/article/26d3d531b4c84fe79dd21d8013090533
Autor:
Takahiko Nakamura, Kenjiro Tsuruoka, Kiyoe Kanaoka, Yosuke Tamura, Yasuhito Fujisaka, Soichiro Ikeda, Tomoya Funamoto, Masafumi Imanishi, Isao Goto, Akihisa Imagawa, Hiroyuki Tsuji, Sho Mitsuya, Ninso Matsunaga
Publikováno v:
Anticancer Research. 41:5137-5145
BACKGROUND For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-T
Autor:
Hirofumi Morihara, Kenjiro Tsuruoka, Shigeo Wakabayashi, Ninso Matsunaga, Michio Asahi, Akihisa Imagawa, Yasuhito Fujisaka, Isao Goto
Publikováno v:
International Journal of Cardiology. 313:67-75
Background Although immune checkpoint inhibitors (ICIs) have made an immense breakthrough in cancer therapeutics, they can exert unique, immune-related adverse events. Among them, myocarditis is less frequent, but it is serious and often follows a le
Autor:
Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yasuto Yoneshima, Ryota Saito, Tomohiro Ozaki, Kenjiro Tsuruoka, Akito Hata, Kosuke Tsuruno, Tomohiro Sakamoto, Shunsuke Teraoka, Masahide Oki, Hiroshi Watanabe, Tomoyuki Otani, Kazuko Sakai, Shuta Tomida, Yasutaka Chiba, Akihiko Ito, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hidetoshi Hayashi
Publikováno v:
Cancer Research. 83:2173-2173
Background: Programmed cell death-ligand 1 (PD-L1) inhibitor durvalumab has been found to improve disease control in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with definitive concurrent chemoradiation therapy (dC
Autor:
Shintaro Kanda, Yutaka Fujiwara, Keisuke Asakura, Kenjiro Tsuruoka, Yuichiro Ohe, Hiroyuki Sakurai, Hiroshi Nokihara, Kazuo Nakagawa, Shun Ichi Watanabe, Noboru Yamamoto, Yasushi Goto, Hidehito Horinouchi, Koji Tsuta
Publikováno v:
Lung Cancer. 108:115-120
Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the
Autor:
H. Tsuji, Kenjiro Tsuruoka, Isao Goto, Yasuhito Fujisaka, Yosuke Tamura, T. Funamoto, Soichiro Ikeda, K. Kanaoka, S. Mitsuya, Masafumi Imanishi, Takahiko Nakamura, Ninso Matsunaga
Publikováno v:
Journal of Thoracic Oncology. 16:S596
Autor:
Yuichiro Ohe, Shintaro Kanda, Yutaka Fujiwara, Hiroshi Nokihara, Emi Kubo, Noboru Yamamoto, Yasushi Goto, Shinsuke Kitahara, Kenjiro Tsuruoka, Koji Tsuta, Yosuke Tamura, Hidehito Horinouchi
Publikováno v:
BMC Research Notes
Background Pulmonary pleomorphic carcinoma (PPC) follows an aggressive clinical course and outcomes are disappointing. Due to its rarity, however, the clinicopathological and molecular characteristics of this disease remain unclear. Methods We retros
Autor:
Tetsufumi Kawaguchi, Yasuhito Fujisaka, Soichiro Ikeda, Isao Goto, Shuhei Yoshida, Yosuke Tamura, Kenjiro Tsuruoka, Takahiko Nakamura, Keiji Miyoshi, Ninso Matsunaga, Masafumi Imanishi
Publikováno v:
Journal of Thoracic Oncology. 12:S914-S915
Autor:
Hirofumi Morihara, Yasuhito Fujisaka, Isao Goto, Shigeo Wakabayashi, Ninso Matsunaga, Kenjiro Tsuruoka, Masaaki, Michio Asahi
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO4-2
Autor:
Yousuke Tamura, Masafumi Imanishi, Kenjiro Tsuruoka, Takahiko Nakamura, Shuhei Yoshida, Ninso Matsunaga, Yasuhito Fujisaka, Soichiro Ikeda, Keiji Miyoshi, Isao Goto
Publikováno v:
Journal of Thoracic Oncology. 12:S682